# Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma

> **NCT01405235** · PHASE3 · UNKNOWN · sponsor: **Institut fuer Frauengesundheit** · enrollment: 312 (estimated)

## Conditions studied

- Recurrent, Persistent or Metastasized Cervical Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin/Paclitaxel

## Key facts

- **NCT ID:** NCT01405235
- **Lead sponsor:** Institut fuer Frauengesundheit
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** 2012-06
- **Final completion:** 2015-01
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2012-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405235, "Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01405235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*